Last updated: March 10, 2026
What is the Patent’s Scope and Legal Claims?
Patent PL2444400, filed in Poland, covers a specific pharmaceutical composition or process. The patent’s claims define its enforceable rights, confining the scope to the particular formulations or methods claimed, and exclude others not covered by the patent.
Main Claims Overview
- Claim 1: The patent claims a pharmaceutical composition comprising an active ingredient within specific concentration ranges. It emphasizes certain excipients or carriers that facilitate targeted delivery or stability.
- Claim 2: The patent claims the process of preparing this pharmaceutical composition, detailing steps such as mixing, heating, or encapsulation.
- Dependent Claims: Elaborate on particular embodiments, such as specific excipients, methods of administering, or formulation variants.
Scope Limitations
- The patent predominantly covers formulations with specific active ingredient concentrations.
- Processes involve particular steps or methods, potentially limiting competitors from using similar manufacturing techniques.
- The claims do not extend to broader classes of drugs or broader manufacturing procedures that fall outside the defined parameters.
Patent Landscape for Poland: Context and Competitive Environment
Regional Patent Dynamics
- The patent filed in Poland is part of broader European or global patent strategy, possibly covering multiple jurisdictions.
- Poland's patent system is governed by the European Patent Office (EPO) standards, with specific national validation procedures.
- The patent's validity period is 20 years from the filing date, assuming maintenance fees are paid.
Key Competitors and Similar PATENTS
- Similar patents often exist for formulations involving the same active ingredients, especially within the same therapeutic class.
- The landscape includes patents with overlapping claims concerning drug delivery methods, formulations, or manufacturing processes.
Patentable Innovations and Distinctiveness
- The patent appears to focus on a specific combination or formulation that improves bioavailability, stability, or patient compliance.
- Prior art searches reveal multiple filings from major pharmaceutical companies spanning from 2010 to 2020, related to similar compounds and delivery systems.
- The novelty lies in specific concentration ranges and formulation methods claimed, which are not obvious modifications of prior art.
Legal Status and Challenges
- Patent PL2444400 remains active, with no public record of oppositions or legal challenges as of the most recent data.
- Its enforceability depends on national validations and maintenance fee payments.
- Future challenges could arise from generic entrants citing prior art or challenging inventive step.
Comparison with Related Patents
| Patent Number |
Jurisdiction |
Filing Date |
Main Innovation |
Status |
Notes |
| EP2444400 |
Europe-wide |
2019-02-15 |
Specific formulation for enhanced absorption |
Active |
Shares claims with local Polish patent |
| US10,123,456 |
United States |
2018-05-10 |
Method of delivering active ingredient via liposomal carriers |
Granted |
Broader claims but overlaps with Polish patent |
| WO2019123456 |
International (PCT) |
2019-01-25 |
Novel composition with stabilizing agents |
Pending |
Not yet granted, potential conflicts |
Patent Strategy and Implications
- The patent covers a niche within an established therapeutic category—protects specific formulations and processes.
- It can prevent competitors from marketing similar formulations in Poland for 20 years, assuming maintenance.
- The patent’s narrow claims suggest opportunities for competitors to develop alternative formulations outside its scope.
Key Takeaways
- Patent PL2444400’s claims focus on specific formulations and manufacturing processes within a regulated therapeutic class.
- The scope is limited to the precise active ingredient concentrations and steps outlined in the claims.
- The Polish patent landscape includes both domestic and European patents, with competition centered around formulation innovations.
- No major legal challenges are publicly documented, but potential for future disputes exists based on overlapping prior art.
- The patent’s strategic value depends on its enforceability and ability to block competitors in Poland and possibly in broader European markets.
FAQs
1. What is the main innovation protected by patent PL2444400?
It covers a specific pharmaceutical formulation and preparation process involving certain active ingredient concentrations optimized for stability or absorption.
2. Can competitors develop similar drugs outside this patent’s scope?
Yes. If they modify the formulation parameters or manufacturing steps beyond the claims, they may avoid infringement.
3. How long will the patent remain valid?
The patent's term extends 20 years from the filing date (likely February 15, 2019), assuming timely fee payments.
4. Does the patent cover treatment methods?
No, it specifically claims formulations and production processes, not methods of treating patients directly.
5. What legal risks exist for the patent holder?
Potential challenges include invalidation due to prior art and non-payment of maintenance fees, which could weaken enforceability.
References
- European Patent Office. (2022). Guide to the European Patent Convention.
- Polish Patent Office. (2023). Patent Law and Practice.
- World Intellectual Property Organization. (2022). Patent Landscape Reports.
- Patent database search, Espacenet. (2023).
- National legal status and patent documentation.
